What is ImaginAb?
Established in 2007 and headquartered in California, ImaginAb operates at the intersection of biotechnology and clinical diagnostics. The company specializes in the development of novel imaging products designed to visualize the immune system's response to therapeutic interventions. By leveraging advanced molecular imaging techniques, ImaginAb enables clinicians to make data-driven decisions, thereby optimizing the efficacy of drug regimens and improving patient outcomes. Its market position is defined by a commitment to addressing the unmet needs in oncology, where precise monitoring of therapeutic response is essential for the success of next-generation immunotherapies.
How much funding has ImaginAb raised?
ImaginAb has raised a total of $59.5M across 6 funding rounds:
Series A
$12.5M
Series B
$21M
Private Equity
$5.3M
Private Equity
$7.7M
Debt
$150K
Other Financing Round
$12.8M
Series A (2012): $12.5M with participation from Mérieux Développement, Momentum Biosciences, Novartis Venture Fund, Cycad Group, and Nextech Invest
Series B (2014): $21M led by Mérieux Développement, Novartis Venture Fund, Cycad Group, and Nextech Invest
Private Equity (2016): $5.3M, investors not publicly disclosed
Private Equity (2017): $7.7M, investors not publicly disclosed
Debt (2020): $150K backed by PPP
Other Financing Round (2021): $12.8M with participation from Norgine, Adage Capital Management, Cycad Group, Theravance Respiratory Company, and Jim Pallotta
Key Investors in ImaginAb
Novartis Venture Fund
Novartis is a global pharmaceutical manufacturer headquartered in Switzerland, specializing in developing and producing innovative medications and healthcare solutions.
Cycad Group
Cycad Group is focused on investing in technology across various sectors, including healthcare and energy, with a strategy emphasizing cutting-edge innovation.
Nextech Invest
Nextech Invest is a Zurich-based firm dedicated to accelerating advancements in precision medicine by identifying and nurturing transformative cancer medicine companies.
What's next for ImaginAb?
With the support of its latest strategic investment, ImaginAb is well-positioned to accelerate the clinical validation of its diagnostic pipeline. The company's roadmap focuses on expanding the utility of its imaging agents across a broader spectrum of therapeutic areas, moving beyond initial oncology applications. As the healthcare sector increasingly shifts toward personalized medicine, ImaginAb's ability to provide actionable, non-invasive insights will likely remain a cornerstone of its growth strategy. Future milestones will likely involve deepening partnerships with global pharmaceutical entities to integrate these imaging solutions into standard clinical trial protocols and routine diagnostic workflows.
See full ImaginAb company page
